Free Trial

Connecticut Wealth Management LLC Has $445,000 Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics logo with Medical background

Connecticut Wealth Management LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,782 shares of the biopharmaceutical company's stock after selling 13,000 shares during the quarter. Connecticut Wealth Management LLC's holdings in TG Therapeutics were worth $445,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TGTX. Bleakley Financial Group LLC bought a new position in TG Therapeutics in the 4th quarter valued at about $245,000. Castellan Group acquired a new stake in TG Therapeutics in the 4th quarter valued at about $8,539,000. Barclays PLC lifted its holdings in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after acquiring an additional 158,323 shares during the last quarter. Stratos Wealth Advisors LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at about $241,000. Finally, Strategic Financial Concepts LLC purchased a new stake in TG Therapeutics during the fourth quarter valued at about $1,404,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.80.

Get Our Latest Research Report on TG Therapeutics

TG Therapeutics Stock Performance

TGTX stock traded down $0.18 during midday trading on Wednesday, hitting $35.06. The stock had a trading volume of 446,727 shares, compared to its average volume of 2,740,934. The firm has a market capitalization of $5.57 billion, a price-to-earnings ratio of -350.54 and a beta of 2.21. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The stock has a 50-day simple moving average of $37.84 and a 200 day simple moving average of $34.36. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same period last year, the business earned ($0.07) earnings per share. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

(Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

See Also

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Should You Invest $1,000 in TG Therapeutics Right Now?

Before you consider TG Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.

While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines